Influenza and antiviral resistance: an overview

被引:212
作者
Lampejo, Temi [1 ]
机构
[1] Royal London Hosp, Bails Hlth NHS Trust, Dept Infect, London, England
关键词
ZANAMIVIR COMBINATION THERAPY; NEURAMINIDASE INHIBITORS; A VIRUS; OSELTAMIVIR RESISTANCE; DRUG-RESISTANCE; EMERGENCE; MUTATIONS; EPIDEMIOLOGY; INFECTIONS; A(H3N2);
D O I
10.1007/s10096-020-03840-9
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Influenza affects approximately 1 billion individuals each year resulting in between 290,000 and 650,000 deaths. Young children and immunocompromised individuals are at a particularly high risk of severe illness attributable to influenza and these are also the groups of individuals in which reduced susceptibility to neuraminidase inhibitors is most frequently seen. High levels of resistance emerged with previous adamantane therapy for influenza A and despite no longer being used to treat influenza and therefore lack of selection pressure, high levels of adamantane resistance continue to persist in currently circulating influenza A strains. Resistance to neuraminidase inhibitors has remained at low levels to date and the majority of resistance is seen in influenza A H1N1 pdm09 infected immunocompromised individuals receiving oseltamivir but is also seen less frequently with influenza A H3N2 and B. Rarely, resistance is also seen in the immunocompetent. There is evidence to suggest that these resistant strains (particularly H1N1 pdm09) are able to maintain their replicative fitness and transmissibility, although there is no clear evidence that being infected with a resistant strain is associated with a worse clinical outcome. Should neuraminidase inhibitor resistance become more problematic in the future, there are a small number of alternative novel agents within the anti-influenza armoury with different mechanisms of action to neuraminidase inhibitors and therefore potentially effective against neuraminidase inhibitor resistant strains. Limited data from use of novel agents such as baloxavir marboxil and favipiravir, does however show that resistance variants can also emerge in the presence of these drugs.
引用
收藏
页码:1201 / 1208
页数:8
相关论文
共 50 条
  • [31] Antiviral resistance in influenza viruses circulating in Central and South America based on the detection of established genetic markers
    Garcia, Josefina
    Sovero, Merly
    Torres, Alberto L.
    Gomez, Jorge
    Douce, Richard
    Barrantes, Melvin
    Sanchez, Felix
    Jimenez, Mirna
    Comach, Guillermo
    de Rivera, Ivette
    Agudo, Roberto
    Kochel, Tadeusz
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2009, 3 (02) : 69 - 74
  • [32] Antiviral resistance testing
    Smit, Erasmus
    CURRENT OPINION IN INFECTIOUS DISEASES, 2014, 27 (06) : 566 - 572
  • [33] Hedging against Antiviral Resistance during the Next Influenza Pandemic Using Small Stockpiles of an Alternative Chemotherapy
    Wu, Joseph T.
    Leung, Gabriel M.
    Lipsitch, Marc
    Cooper, Ben S.
    Riley, Steven
    PLOS MEDICINE, 2009, 6 (05):
  • [34] Influenza Virus: A Brief Overview
    Dangi, Tanushree
    Jain, Amita
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES INDIA SECTION B-BIOLOGICAL SCIENCES, 2012, 82 (01) : 111 - 121
  • [35] Secondary substitutions in the hemagglutinin and neuraminidase genes associated with neuraminidase inhibitor resistance are rare in the Influenza Resistance Information Study (IRIS)
    Roosenhoff, Rueshandra
    Schutten, Martin
    Reed, Vaughan
    Clinch, Barry
    van der Linden, Anne
    Fouchier, Ron A. M.
    Fraaij, Pieter L. A.
    ANTIVIRAL RESEARCH, 2021, 189
  • [36] Antiviral Drugs in Influenza
    Swierczynska, Magdalena
    Mirowska-Guzel, Dagmara M.
    Pindelska, Edyta
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (05)
  • [37] Antiviral Treatments for Influenza
    Palomba, Emanuele
    Castelli, Valeria
    Renisi, Giulia
    Bandera, Alessandra
    Lombardi, Andrea
    Gori, Andrea
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 42 (06) : 859 - 871
  • [38] Antiviral Drugs for Influenza
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2020, 62 (1589): : 1 - 4
  • [39] Antiviral therapies for influenza
    Chan, Ken K. P.
    Hui, David S. C.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2023, 36 (02) : 124 - 131
  • [40] Antiviral Drugs for Influenza
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1355): : 1 - 3